“Take out your phone and open your ChatGPT app. Type this prompt: ‘Based on my past conversations, analyze my behavioral tendencies.'”
In a Reddit post that has gone viral, that’s what someone claims just happened to them during a job interview.
If that interview scenario is real, the issues aren’t just ethical. They’re also potentially
Bradley Heppner likely could have afforded to retain any lawyer of his choosing, having allegedly defrauded investors out of $150 million. But he chose a somewhat different path. Whether it was because he believed himself to be better, or more motivated, than a lawyer, or was just a hands-on kinda guy, who knows. but he
Author: Pat Pascarella
AI will weaponize antitrust. AI markets have high fixed costs, winner-take-all dynamics, platform leverage, bundling power, and data lock-in. These dynamics predict concentration. And market concentration is an accelerant for antitrust litigation—both private and government. We saw it with IBM, Microsoft, and the telecom wars.
Private actions will move faster than government
Legal CRMs simplify client management and improve retention by centralizing data, automating communication, and identifying at-risk clients. Losing clients is costly – not just in revenue but in future opportunities and reputation. Studies show a 5% increase in retention can boost profits by 25% to 95%. Here’s how legal CRMs help:
With the impact of artificial intelligence (AI) on everyone’s mind, companies are seeing investors ask an increasing number of AI-focused questions in shareholder engagement meetings. These questions reflect a growing consensus among institutional investors that effective AI governance is inextricably linked to fiduciary duty, long-term financial performance, and sustainable economic growth drivers. Although the answers to these questions are necessarily company-specific, we believe that it is important for companies to prepare for AI-related questions from investors.
I’m excited to announce that I will be the panel chair and moderator for “Artificial Intelligence & Trade Secrets” at the New York City Bar Association’s Trade Secret Symposium 2026 on Friday, February 20, 2026 at 9:00 a.m. ET. I’ll have the honor of facilitating a panel composed of AI experts Matthew D’Amore of Cornell
Retailers. Banks. Healthcare systems. E-commerce platforms. Across industries, live chat, session replay software, and website analytics have become standard tools for customer engagement. These technologies help businesses respond to consumer inquiries in real time, improve website functionality, reduce cart abandonment, train customer service teams, and resolve disputes.
For companies operating nationally, the landscape is shifting
In a recent addition to the EU’s evolving digital rulebook, the European Commission has published a set of Guidelines under the European Media Freedom Act (“EMFA”). The Guidelines advise very large online platforms, as defined under the Digital Services Act (“DSA”), on how to set up a functionality that lets media organisations identify themselves—and, in
Navigating Simplification Without Sacrificing Safeguards: Key Takeaways
As the EU begins the complex task of making the European Artificial Intelligence Act[1] (the “AI Act”) workable in real life, the European Commission’s Proposal for a Regulation amending Regulations (EU) 2024/1689 and (EU) 2018/1139 as regards the simplification of the implementation of harmonised rules
The UK Medicines and Healthcare products Regulatory Agency (“MHRA”) has published a targeted consultation on the indefinite recognition of the CE-mark for medical devices placed on the market in Great Britain (“GB”) (i.e., England, Scotland and Wales) (the “Consultation”), which will run until 10 April 2026. The Consultation aims to complement wider planned reforms to the UK medical device regulatory framework that are expected to be announced later this year. The Consultation applies to GB only as medical devices placed on the Northern Ireland market must comply with the EU medical devices framework and be CE-marked in any event.
The Consultation follows an earlier public consultation on pre-market regulatory changes for medical devices and in vitro diagnostic (“IVD”) devices (see our prior blog post here), where the MHRA announced its intention to further consult on the indefinite recognition of CE-marked medical devices in GB.